Merck & Company, Inc. (NYSE:MRK) was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Monday. They presently have a $56.00 target price on the stock. Morgan Stanley’s target price would suggest a potential upside of 1.65% from the stock’s current price.
Several other equities research analysts have also issued reports on the company. SunTrust Banks, Inc. lowered Merck & from a “buy” rating to a “hold” rating in a report on Monday. Barclays PLC lowered Merck & from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $72.00 to $62.00 in a report on Monday. Leerink Swann lifted their price target on Merck & from $69.00 to $70.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Jefferies Group LLC reiterated a “sell” rating and set a $55.00 price target on shares of Merck & in a report on Friday, October 20th. Finally, BMO Capital Markets set a $70.00 price target on Merck & and gave the company a “buy” rating in a report on Wednesday, October 18th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $67.07.
Shares of Merck & (NYSE:MRK) opened at 55.09 on Monday. The firm has a market cap of $150.25 billion, a P/E ratio of 29.83 and a beta of 0.80. The company’s 50-day moving average is $63.71 and its 200-day moving average is $63.55. Merck & has a 52-week low of $54.41 and a 52-week high of $66.80.
Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. The business had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The firm’s revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.07 EPS. Equities research analysts forecast that Merck & will post $3.92 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of MRK. Perennial Advisors LLC increased its position in Merck & by 10.7% in the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after buying an additional 157 shares during the period. Stelac Advisory Services LLC bought a new position in Merck & in the 2nd quarter worth approximately $104,000. Vigilant Capital Management LLC increased its position in Merck & by 16.7% in the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares during the period. Cascade Investment Advisors Inc. increased its position in Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after buying an additional 232 shares during the period. Finally, Solaris Asset Management LLC increased its position in Merck & by 6.3% in the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock worth $124,000 after buying an additional 115 shares during the period. 72.86% of the stock is currently owned by institutional investors.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.